J&J: positive data on nipocalimab
(CercleFinance.com) - Johnson & Johnson announces the publication of data on the differentiated molecular properties of nipocalimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn).
These preclinical studies show that nipocalimab binds specifically and with high affinity to FcRn, resulting in a reduction of over 75% in circulating IgG (immunoglobulin G) without affecting its production or other immune functions.
These features could make it a therapeutic option for IgG autoantibody diseases such as generalized myasthenia gravis.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
These preclinical studies show that nipocalimab binds specifically and with high affinity to FcRn, resulting in a reduction of over 75% in circulating IgG (immunoglobulin G) without affecting its production or other immune functions.
These features could make it a therapeutic option for IgG autoantibody diseases such as generalized myasthenia gravis.
Copyright (c) 2025 CercleFinance.com. All rights reserved.